BIO Opposes Terms "Comparability" & "Therapeutic Equivalence" For Follow-On Biologics
This article was originally published in The Pink Sheet Daily
Executive Summary
The industry organization continues to emphasize the need for full clinical testing for follow-on biologics. BIO acknowledges that an abbreviated regulatory process may be possible in the future for certain follow-on products.
You may also be interested in...
Analytical Test Series Would Allow Characterization Of Follow-On Biologics – GPhA
"No 'one' analytical method is currently capable of such comprehensive analysis," a Generic Pharmaceutical Association white paper states. Previously reported characterization problems were due to inappropriate or misinterpreted tests, GPhA maintains.
FDA Will Release Follow-On Biologics Background Document By Year-End
The document will illustrate prior regulatory treatment paths for natural source-derived and biotech protein products, so it should not cause any controversy, Acting Commissioner for Operations Woodcock says.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.